Grupo-Publicaciones-GIIS023
16 julio, 2019Grupo-Publicaciones-GIIS026
16 julio, 2019Paz-Ares L, O’Brien M, Mauer M, Dafni U, Oselin K, Havel L, Gonzalez E, Isla Casado D, Martinez-Marti A, Faehling M, Tsuboi M, Lee J, Nakagawa K, Yang J, Keller S, Jha N, Marreaud S, Stahel R, Peters S, Besse B. VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 e PEARLS/KEYNOTE-091 study. ANNALS OF ONCOLOGY. 2022. 10.1016/j.annonc.2022.02.224. FI-56,7
Mulcahy M, Mahvash A, Pracht M, Montazeri A, Bandula S, Martin R, Herrmann K, Brown E, Zuckerman D, Wilson G, Kim T, Weaver A, Ross P, Harris W, Graham J, Mills J, Yubero Esteban A, Johnson M, Sofocleous C, Padia S, Lewandowski R, Garin E, Sinclair P, Salem R, EPOCH Investigators . Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.. JOURNAL OF CLINICAL ONCOLOGY. 2021. 10.1200/JCO.21.01839. FI-42,1
O’Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla Casado D, Martinez-Marti A, Faehling M, Tsuboi M, Lee J, Nakagawa K, Yang J, Samkari A, Keller S, Mauer M, Jha N, Stahel R, Besse B, Peters S, EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators . Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.. LANCET ONCOLOGY. 2022. 10.1016/S1470-2045(22)00518-6. FI-41,6
Ramírez Labrada A, Isla Casado D, Artal Cortés A, Arias Cabrero M, Rezusta López A, Pardo J, Galvez E. The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy. Trends in Cancer. 2020. 10.1016/j.trecan.2019.12.007. FI-14,3
Peressini M, Garcia-Campelo R, Massuti B, Marti C, Cobo M, Gutiérrez V, Dómine M, Fuentes J, Majem M, de Castro J, Cordoba J, Diz M, Isla Casado D, Esteban E, Carcereny E, Vila L, Moreno-Vega A, Ros S, Moreno A, Garcia F, Huidobro G, Aguado C, Cebey-Lopez V, Valdivia J, Palmero R, Lianes P, Lopez-Brea M, Vidal O, Provencio M, Arriola E, Baena J, Herrera M, Bote H, Molero M, Adradas V, Ponce-Aix S, Nuñez-Buiza A, Ucero Á, Hernandez S, Lopez-Rios F, Conde E, Paz-Ares L, Zugazagoitia J. Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.. Clinical Cancer Research. 2024. 10.1158/1078-0432.CCR-24-0104. FI-10,4
Goss G, Cobo M, Lu S, Syrigos K, Lee K, Göker E, Georgoulias V, Isla Casado D, Morabito A, Min Y, Ardizzoni A, Bender S, Cseh A, Felip E. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial.. Eclinicalmedicine. 2021. 10.1016/j.eclinm.2021.100940. FI-9,6
Isla Casado D, Majem M. A Paradigm Shift for Resectable Non-Small Cell Lung Cancer.. Archivos De Bronconeumologia. 2022. 10.1016/j.arbres.2022.04.004. FI-8,7
Cueva J, Palacio I, Churruca C, Herrero Ibañez A, Pardo B, Constenla M, Santaballa A, Manso L, Estevez P, Maximiano C, Legeren M, Marquina G, de Juan A, Quindos M, Sanchez L, Barquin A, Fernandez I, Martin C, Juarez A, Martin T, Garcia Y, Yubero Esteban A, Gallego A, Bueno A, Guerra E, Gonzalez-Martin A. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme. EUROPEAN JOURNAL OF CANCER. 2023. 10.1016/j.ejca.2022.12.023. FI-7,6
Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, Califano R, Carcereny E, Griffiths R, Paz-Ares L, Duchnowska R, Alonso Garcia M, Isla Casado D, Jassem J, Appel W, Milanowski J, Van Meerbeeck J, Wolf J, Li A, Acevedo A, Popat S. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. EUROPEAN JOURNAL OF CANCER. 2020. 10.1016/j.ejca.2019.11.019. FI-7,6
Elez E, Ayala F, Felip E, García Campelo R, García Carbonero R, García Donás J, González Del Alba A, González Flores E, Hidalgo J, Isla Casado D, Majem M, Rodríguez Lescure Á, Safont M, Santaballa A, Villacampa G, Vera R, Garrido P. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM).. ESMO Open. 2021. 10.1016/j.esmoop.2021.100048. FI-7,1
